Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11932071 | 1.00 | ALDH1A1 (0.33) | ALDH1A1TDP1CHRM2CHRM1CHRM3 | |
| SCHEMBL23765298 | 1.00 | ALDH1A1 (0.33) | ALDH1A1TDP1CHRM2CHRM1CHRM3 | |
| SCHEMBL25520261 | 0.86 | — | — | |
| SCHEMBL2125652 | 0.84 | ALDH1A1 (0.36) | ALDH1A1TDP1USP2GAAMAPT | |
| SCHEMBL20900595 | 0.81 | CHRM2 (0.31) | ALDH1A1TDP1CHRM2CHRM1CHRM3 | |
| SCHEMBL20381734 | 0.81 | CHRM2 (0.31) | ALDH1A1TDP1CHRM2CHRM1CHRM3 | |
| SCHEMBL1091004 | 0.78 | APLNR (0.33) | — | |
| SCHEMBL17465649 | 0.78 | ALDH1A1 (0.37) | ALDH1A1TDP1 | |
| SCHEMBL20402853 | 0.78 | CHRM2 (0.32) | CHRM2CHRM1CHRM3 | |
| SCHEMBL22623987 | 0.78 | KDM4E (0.41) | CHRM2CHRM1CHRM3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253614-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CD73 | PELOTON THERAPEUTICS, INC. (US) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253614-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CD73 | ENTPD5, NT5E, ENTPD1 | ALDH1A1 868/4885TDP1 342/4885CHRM2 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.